1-5 of 5
Lona Gaugler
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Multivariable-adjusted validation of IWG23-defined peripheral blood complete remission (PB-CR) and IWG23 response criteria in 2,042 patients with MDS, CMML or AML treated with diverse first-line therapies: Insights from the AML-001 trial (NCT01074047) and the ‘austrian myeloid registry’ (NCT04438889) of the AGMT study group

Free
Lisa Pleyer, Xu Zhang, Manuel Drost, Hubert Angermann, Julia Oberlechner, Michael Pfeilstöcker, Verena Petzer, Sonja Heibl, Jennifer Moritz, Michael Girschikofsky, Margarete Stampfl-Mattersberger, Angelika Pichler, Bernd Hartmann, Gregor Aschauer, Clemens Schmitt, Sonia Vallet, Szilvia Boros, Petra Pichler, Andrea Hammerl-Steiner, Johannes Andel, Jan Philipp Bewersdorf, Amer Zeidan, Daniel Lopes de Menezes, Thomas Prebet, Thomas Melchardt, Richard Greil, Lona Gaugler
Journal: Blood
Blood (2025) 146 (Supplement 1): 3859.
https://doi.org/10.1182/blood-2025-3859
Published: 2025
Journal Articles

Time-dependent long short-term memory neural cox regression in 2,690 patients with myeloid neoplasias treated with diverse therapies identifies bone marrow related information to be less important than expected in the context of other available clinical parameters: Insights from the AML-001 trial (NCT01074047) and the austrian myeloid registry (NCT04438889) of the AGMT study group

Free
Lisa Pleyer, Xu Zhang, Manuel Drost, Julia Oberlechner, Hubert Angermann, Michael Pfeilstöcker, Verena Petzer, Sonja Heibl, Jennifer Moritz, Michael Girschikofsky, Margarete Stampfl-Mattersberger, Angelika Pichler, Bernd Hartmann, Gregor Aschauer, Clemens Schmitt, Sonia Vallet, Szilvia Boros, Petra Pichler, Andrea Hammerl-Steiner, Johannes Andel, Daniel Lopes de Menezes, Thomas Prebet, Amer Zeidan, Nadja Zaborsky, Richard Greil, Thomas Melchardt, Lona Gaugler, Jan Hasenauer, Marc Vaisband
Journal: Blood
Blood (2025) 146 (Supplement 1): 48.
https://doi.org/10.1182/blood-2025-48
Published: 2025
Journal Articles

Intensive Chemotherapy (IC) Followed By Oral Azacitidine (AZA) Maintenance Versus Venetoclax (VEN) Plus AZA for Patients (pts) with Acute Myeloid Leukemia (AML): Retrospective Analysis of an Electronic Medical Record (EMR) Database in the United States

Free
Alice Mims, Zhuoer Xie, Alberto Vasconcelos, Maria Strocchia, Lona Gaugler, Sara Vergara, Ying Qiu, David Rotter, Ravi Potluri, Thomas Prebet, Jan Sieluk
Journal: Blood
Blood (2023) 142 (Supplement 1): 550.
https://doi.org/10.1182/blood-2023-173442
Published: 2023
Journal Articles

Matching Adjusted Indirect Comparison (MAIC) of Oral Azacitidine (Oral-AZA) Versus Injectable AZA in Patients (pts) with Acute Myeloid Leukemia (AML) in First Remission after Intensive Induction Chemotherapy

Free
Clara Chen, Gerwin A. Huls, Heather Cameron, Beatrice Suero, Alberto Vasconcelos, Lona Gaugler, C.L. Beach
Journal: Blood
Blood (2021) 138 (Supplement 1): 3015.
https://doi.org/10.1182/blood-2021-148049
Published: 2021
Journal Articles

Venetoclax Plus Azacitidine (VEN-AZA) Vs. Intensive Chemotherapy (IC) As Induction for Patients with Acute Myeloid Leukemia (AML): Retrospective Analysis of an Electronic Medical Records (EMR) Database in the United States

Free
Amer M. Zeidan, Daniel A. Pollyea, Uma Borate, Alberto Vasconcelos, Ravi Potluri, David Rotter, Zephirin Kiendrebeogo, Lona Gaugler, Gaetano Bonifacio, Clara Chen
Journal: Blood
Blood (2021) 138 (Supplement 1): 277.
https://doi.org/10.1182/blood-2021-147926
Published: 2021